title: Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients.
authors.forename: Enver
authors.initials: E
authors.lastname: Akalin
authors.forename: Scott
authors.initials: S
authors.lastname: Ames
authors.forename: Vinita
authors.initials: V
authors.lastname: Sehgal
authors.forename: Barbara
authors.initials: B
authors.lastname: Murphy
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Bromberg
authors.forename: Marilena
authors.initials: M
authors.lastname: Fotino
authors.forename: Rex
authors.initials: R
authors.lastname: Friedlander
mesh_terms: D000961:Antilymphocyte Serum / Q000276:immunology* / Q000627:therapeutic use; D004198:Disease Susceptibility; D005260:Female; D006084:Graft Rejection / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology* / Q000627:therapeutic use*; D007167:Immunotherapy; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D014180:Transplantation
chemical_list: D000961:Antilymphocyte Serum; D016756:Immunoglobulins, Intravenous